Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries, a generic pharmaceutical company, and Sweden-based pharmaceutical company Active Biotech have announced that oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis, has received a fast track designation from the FDA.
Subscribe to our email newsletter
Teva has completed enrollment for the first of its two Phase III clinical trials for laquinimod (Allegro) in November 2008 and is currently enrolling relapsing-remitting multiple sclerosis (RRMS) patients globally for the second Phase III study (Bravo).
Moshe Manor, vice president of global innovative resources group at Teva, said: “As global leaders in the treatment of multiple sclerosis, Teva is committed to bringing additional safe, effective and convenient therapies to MS patients. We are pleased that the FDA has awarded laquinimod with a fast track designation, and are hopeful it will be part of our growing portfolio of innovative therapies.”